- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06343298
Evaluar la seguridad y eficacia de MANP en sujetos con hipertensión resistente o difícil de controlar (BOLD-HTN)
Un estudio de fase 2, doble ciego, controlado con placebo, de titulación de dosis para evaluar la seguridad y eficacia de SQ MANP cuando se administra diariamente durante aproximadamente 42 días en sujetos con hipertensión difícil de controlar / hipertensión resistente
This is a Phase 2 dose-titration study designed to evaluate the safety and efficacy of MANP subcutaneous injection compared to placebo in reducing baseline daytime systolic blood pressure (SBP), derived from 24-hour ambulatory blood pressure monitoring (ABPM), in subjects with hypertension who are taking 3 or more antihypertensive medications with different mechanisms of action.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Seetha R Iyer, MS
- Número de teléfono: 212-271-4295
- Correo electrónico: sri@icw.ventures
Copia de seguridad de contactos de estudio
- Nombre: Lucia Gonzalez
Ubicaciones de estudio
-
-
Arkansas
-
Little Rock, Arkansas, Estados Unidos, 72204
- Reclutamiento
- Lynn Institute of the Ozarks
-
Contacto:
- BOLD-HTN
- Correo electrónico: bold-HTN@estar.bio
-
-
California
-
Lake Forest, California, Estados Unidos, 92630
- Reclutamiento
- Orange County Research Center
-
Contacto:
- BOLD-HTN, BSME
- Correo electrónico: bold-HTN@estar.bio
-
Westlake Village, California, Estados Unidos, 91361
- Reclutamiento
- Office of Dr. Edward Portnoy MD
-
Contacto:
- BOLD-HTN
- Correo electrónico: bold-HTN@estar.bio
-
-
Florida
-
Daytona Beach, Florida, Estados Unidos, 32117
- Reclutamiento
- Arrow Clinical Trials
-
Contacto:
- BOLD-HTN
- Correo electrónico: bold-HTN@estar.bio
-
Hollywood, Florida, Estados Unidos, 33021
- Reclutamiento
- Royal Research Corp
-
Contacto:
- BOLD-HTN
- Correo electrónico: bold-HTN@estar.bio
-
Miami, Florida, Estados Unidos, 33122
- Reclutamiento
- Evolution Clinical Trials
-
Contacto:
- BOLD-HTN
- Correo electrónico: bold-HTN@estar.bio
-
-
Georgia
-
Acworth, Georgia, Estados Unidos, 30101
- Reclutamiento
- Cowry Health
-
Contacto:
- BOLD-HTN
- Correo electrónico: bold-HTN@estar.bio
-
Union City, Georgia, Estados Unidos, 30291
- Reclutamiento
- SKY CRNG
-
Contacto:
- Correo electrónico: boldhtn@estar.bio
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60607
- Reclutamiento
- Cedar Crosse Research Center
-
Contacto:
- BOLD-HTN
- Correo electrónico: bold-HTN@estar.bio
-
-
Michigan
-
Dearborn, Michigan, Estados Unidos, 48126
- Reclutamiento
- Revival Research Institute, LLC
-
Contacto:
- BOLD-HTN
- Correo electrónico: bold-HTN@estar.bio
-
Flint, Michigan, Estados Unidos, 48504
- Reclutamiento
- Aa Mrc Llc
-
Contacto:
- Bold-HTN
- Correo electrónico: bold-HTN@estar.bio
-
-
Mississippi
-
Ridgeland, Mississippi, Estados Unidos, 39157
- Reclutamiento
- SKY CRNG
-
Contacto:
- Correo electrónico: boldhtn@estar.bio
-
-
New York
-
New York, New York, Estados Unidos, 10029
- Reclutamiento
- Mt.Sinai
-
Contacto:
- Correo electrónico: boldhtn@estar.bio
-
-
North Carolina
-
Monroe, North Carolina, Estados Unidos, 28112
- Reclutamiento
- Monroe Biomedical Research
-
Contacto:
- BOLD-HTN
- Correo electrónico: bold-HTN@estar.bio
-
-
Texas
-
Coppell, Texas, Estados Unidos, 75019
- Activo, no reclutando
- Prime Research
-
Dallas, Texas, Estados Unidos, 75230
- Reclutamiento
- Dallas Renal Group
-
Contacto:
- BOLD-HTN
- Correo electrónico: bold-HTN@estar.bio
-
Denton, Texas, Estados Unidos, 76210
- Reclutamiento
- Revival Research
-
Contacto:
- Correo electrónico: boldhtn@estar.bio
-
Houston, Texas, Estados Unidos, 77099
- Reclutamiento
- Pioneer Research Solutions
-
Contacto:
- BOLD-HTN
- Correo electrónico: bold-HTN@estar.bio
-
Houston, Texas, Estados Unidos, 77074
- Reclutamiento
- Aavon Clinical research
-
Contacto:
- Correo electrónico: bold-htn@estar.bio
-
Mansfield, Texas, Estados Unidos, 76063
- Reclutamiento
- Prime Clinical Research
-
Contacto:
- BOLD-HTN
- Correo electrónico: bold-HTN@estar.bio
-
Plano, Texas, Estados Unidos, 75075
- Reclutamiento
- Clinical Investigations of Texas
-
Contacto:
- BOLD-HTN
- Correo electrónico: bold-HTN@estar.bio
-
Richmond, Texas, Estados Unidos, 77407
- Reclutamiento
- Aavon Clinical Trials
-
Contacto:
- BOLD-HTN
- Correo electrónico: bold-HTN@estar.bio
-
Sherman, Texas, Estados Unidos, 75092
- Reclutamiento
- Revival Research
-
Contacto:
- BOLD-HTN
- Correo electrónico: bold-HTN@estar.bio
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
Subjects will be eligible for enrollment in the study only if they meet ALL the following criteria at time of Screening:
- Male or female subjects aged 18 - 80 years, inclusive, at the screening visit.
- Female subjects must not be of childbearing potential
- Subjects must be taking appropriate doses of 2 or more antihypertensive drugs with different mechanisms of action. One of which must be a diuretic and the other must be an ACEi or ARB at atleast 50% of the maximum recommended dose for hypertension.
- Subjects must have a seated (5 minutes) systolic blood pressure ≥ 140 mmHg and SBP ≥130 mmHg by ABPM prior to randomization (T1).
- Subjects must have a CKD-EPI eGFR ≥ 30 mL/min/1.73m2
- A subset of the subjects with an eGFR between 20-30 ml/min/1.73m2 will be included, not to exceed 10% of the total study subjects.
- Subjects must have a BMI between 18 - 40 kg/m2.
- Subjects who engage in sexual intercourse in which their partner could become pregnant must agree to use a barrier method of birth control (i.e., vaginal/penile condom) with spermicide for the duration of the study and for 90 days after the last dose of study drug or be at least 6 weeks post-vasectomy with confirmation by post-vasectomy semen analysis. In addition, subjects may not donate sperm for the duration of the study and for 90 days after the last dose of study drug.
Exclusion Criteria:
Subjects meeting ANY of the following criteria at time of Screening will be excluded from enrollment:
- Subjects with an average sitting systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥ 110 mmHg at Screening (SV), or prior to randomization at T1.
- Subjects with a history of secondary hypertension, including but not limited to coarctation of the aorta, primary hyperaldosteronism, renal artery stenosis, Cushing's disease, pheochromocytoma, and polycystic kidney disease. If the subject has not previously been evaluated for secondary hypertension, investigators are responsible for evaluating all potential secondary causes of hypertension in accordance with current practices and clinical guidelines before entering the patient into the study.
- Subjects with an HbA1c ≥ 8% at screening (SV)
- Subjects who have experienced myocardial infarction, unstable angina, or a cerebrovascular accident (CVA) within 6 months of the Screening Visit; or sick sinus syndrome or second- or third-degree atrioventricular block, or recurrent atrial tachyarrhythmia, recurrent ventricular tachycardia, or symptomatic bradycardia.
- Subjects who have an implanted cardioverter defibrillator (ICD) that has been fired for any arrhythmia within 3 months of Screening (SV) or implanted pacemakers.
- Subjects with congestive heart failure (New York Heart Association [NYHA] class II-IV)
- Subjects with hemodynamically significant valvular heart disease
- Subjects undergoing hemodialysis or peritoneal dialysis, or history of renal transplant.
- Subjects who have diagnosis or recurrence of malignancy within the past 3 years
- Subjects with a documented history of sleep apnea, with a prescription for CPAP therapy.
- Women of childbearing potential
- Subjects who are pregnant or breastfeeding
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador de placebos: Placebo-matched control
Placebo-matched vehicle (vehicle minus the active component) |
This is a placebo matched vehicle - Vehicle minus the active ingredient |
|
Comparador activo: MANP
MANP in vehicle |
MANP (modified atrial natriuretic peptide) is a peptide that is being developed for treatment of difficult to control/resistant hypertension. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change from baseline in mean daytime SBP derived from 24-hour ABPM at approximately Day 42.
Periodo de tiempo: Approximately 42 days
|
ABPM |
Approximately 42 days
|
|
Incidence and severity of Adverse events through 4- weeks post end of treatment.
Periodo de tiempo: Approximately 10 weeks
|
Safety |
Approximately 10 weeks
|
|
Incidence and severity of Serious Adverse Events through 4- weeks post end of treatment.
Periodo de tiempo: Approximately 10 weeks
|
Safety |
Approximately 10 weeks
|
|
Incidence and severity of Treatment Emergent Adverse Events through 4- weeks post end of treatment.
Periodo de tiempo: Approximately 10 weeks
|
Safety |
Approximately 10 weeks
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Clinic sitting systolic blood pressure
Periodo de tiempo: Approximately 42 days
|
Achieving mean seated (5 minutes) systolic blood pressure blood pressure control ≤ 130 mmHg at end of treatment visit. |
Approximately 42 days
|
|
Pharmacokinetics - Cmax
Periodo de tiempo: Approximately 42 days
|
Maximum concentration of MANP in plasma post dose on Day 1 and Last day of Treatment |
Approximately 42 days
|
|
Pharmacokinetics - Tmax
Periodo de tiempo: Approximately 42 Days
|
Time required to achieve maximum concentration of MANP in plasma post dose on Day 1 and Last day of Treatment |
Approximately 42 Days
|
|
Anti-drug Antibody
Periodo de tiempo: Approximately 10 weeks
|
Change in Anti-drug antibodies against MANP and ANP at Days 21 and 42 post treatment and at follow up visits 1 and 2 compared to baseline |
Approximately 10 weeks
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Differential Outcomes in African-American Subject versus Non-African American Subjects
Periodo de tiempo: Approximately 42 days
|
Change mean daytime SBP from ABPM, from baseline compared to end of treatment visit in African American population and the non-African American population at each dose level. |
Approximately 42 days
|
|
Metabolic biomarkers - Glucose
Periodo de tiempo: Approximately 10 weeks
|
Change from baseline in plasma Glucose at end of treatment and Follow-up |
Approximately 10 weeks
|
|
Metabolic biomarkers - Insulin
Periodo de tiempo: Approximately 10 weeks
|
Change from baseline in plasma Insulin at end of treatment and Follow-up |
Approximately 10 weeks
|
|
Metabolic biomarkers - HbA1C
Periodo de tiempo: Approximately 10 weeks
|
Change from baseline in HbA1C at end of treatment and Follow-up |
Approximately 10 weeks
|
|
Lipid biomarkers - HDL
Periodo de tiempo: Approximately 10 weeks
|
Change from baseline in plasma High density Lipoprotein (HDL) at end of treatment and Follow-up |
Approximately 10 weeks
|
|
Lipid biomarkers - LDL
Periodo de tiempo: Approximately 10 weeks
|
Change from baseline in plasma Low density Lipoprotein (LDL) at end of treatment and Follow-up |
Approximately 10 weeks
|
|
Lipid biomarkers - TG
Periodo de tiempo: Approximately 10 weeks
|
Change from baseline in plasma Triglycerides (TG) at end of treatment and Follow-up |
Approximately 10 weeks
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: David Smith, MD, E-Star BioTech, LLC
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
- ES_MANP_2001
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
All IPD that support publications
Marco de tiempo para compartir IPD
As needed for publication support
Criterios de acceso compartido de IPD
IPD will be shared with approved collaborators
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- RSC
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .